Neuralstem files lawsuit against StemCells
As a result of these actions, Neuralstem is asking for a declaratory judgment that the patent is unenforceable. The suit was filed in the US District Court of
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.